<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/allregs/css/uswds.min.css">
    <link rel="stylesheet" href="/allregs/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/allregs/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/allregs/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/titles/title38.html">
                                    Title 38
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/parts/38CFR4.html">Part 4
                                </a><span>&nbsp/&nbsp<span>
                                Sec.  4.119  Schedule of ratings--endocrine system.------------------------------------------------------------------------
                            </h3>
                            <p class="depth0">Rating------------------------------------------------------------------------7900 Hyperthyroidism</p><p class="depth0">Thyroid enlargement, tachycardia (more than 100 beats per          100</p><p class="depth0">minute), eye involvement, muscular weakness, loss of weight,</p><p class="depth0">and sympathetic nervous system, cardiovascular, or</p><p class="depth0">astrointestinal symptoms.....................................</p><p class="depth0">Emotional instability, tachycardia, fatigability, and               60</p><p class="depth0">increased pulse pressure or blood pressure...................</p><p class="depth0">Tachycardia, tremor, and increased pulse pressure or blood          30</p><p class="depth0">pressure.....................................................</p><p class="depth0">Tachycardia, which may be intermittent, and tremor, or;             10</p><p class="depth0">continuous medication required for control...................</p><p class="depth0">Note (1): If disease of the heart is the predominant finding,</p><p class="depth0">evaluate as hyperthyroid heart disease (DC 7008) if doing so</p><p class="depth0">would result in a higher evaluation than using the criteria</p><p class="depth0">above.</p><p class="depth0">Note (2): If ophthalmopathy is the sole finding, evaluate as</p><p class="depth0">field vision, impairment of (DC 6080); diplopia (DC 6090); or</p><p class="depth0">impairment of central visual acuity (DC 6061-6079).7901 Thyroid gland, toxic adenoma of</p><p class="depth0">Thyroid enlargement, tachycardia (more than 100 beats per          100</p><p class="depth0">minute), eye involvement, muscular weakness, loss of weight,</p><p class="depth0">and sympathetic nervous system, cardiovascular, or</p><p class="depth0">gastrointestinal symptoms....................................</p><p class="depth0">Emotional instability, tachycardia, fatigability, and               60</p><p class="depth0">increased pulse pressure or blood pressure...................</p><p class="depth0">Tachycardia, tremor, and increased pulse pressure or blood          30</p><p class="depth0">pressure.....................................................</p><p class="depth0">Tachycardia, which may be intermittent, and tremor, or;             10</p><p class="depth0">continuous medication required for control...................</p><p class="depth0">Note (1): If disease of the heart is the predominant finding,</p><p class="depth0">evaluate as hyperthyroid heart disease (DC 7008) if doing so</p><p class="depth0">would result in a higher evaluation than using the criteria</p><p class="depth0">above.</p><p class="depth0">Note (2): If ophthalmopathy is the sole finding, evaluate as</p><p class="depth0">field vision, impairment of (DC 6080); diplopia (DC 6090); or</p><p class="depth0">impairment of central visual acuity (DC 6061-6079).7902 Thyroid gland, nontoxic adenoma of</p><p class="depth0">With disfigurement of the head or neck........................      20</p><p class="depth0">Without disfigurement of the head or neck.....................       0</p><p class="depth0">Note: If there are symptoms due to pressure on adjacent organs</p><p class="depth0">such as the trachea, larynx, or esophagus, evaluate under the</p><p class="depth0">diagnostic code for disability of that organ, if doing so</p><p class="depth0">would result in a higher evaluation than using this</p><p class="depth0">diagnostic code.7903 Hypothyroidism</p><p class="depth0">Cold intolerance, muscular weakness, cardiovascular                100</p><p class="depth0">involvement, mental disturbance (dementia, slowing of</p><p class="depth0">thought, depression), bradycardia (less than 60 beats per</p><p class="depth0">minute), and sleepiness......................................</p><p class="depth0">Muscular weakness, mental disturbance, and weight gain........      60</p><p class="depth0">Fatigability, constipation, and mental sluggishness...........      30</p><p class="depth0">Fatigability, or; continuous medication required for control..      107904 Hyperparathyroidism</p><p class="depth0">Generalized decalcification of bones, kidney stones,               100</p><p class="depth0">gastrointestinal symptoms (nausea, vomiting, anorexia,</p><p class="depth0">constipation, weight loss, or peptic ulcer), and weakness....</p><p class="depth0">Gastrointestinal symptoms and weakness........................      60</p><p class="depth0">Continuous medication required for control....................      10</p><p class="depth0">Note: Following surgery or treatment, evaluate as digestive,</p><p class="depth0">skeletal, renal, or cardiovascular residuals or as endocrine</p><p class="depth0">dysfunction.7905 Hypoparathyroidism</p><p class="depth0">Marked neuromuscular excitability (such as convulsions,            100</p><p class="depth0">muscular spasms (tetany), or laryngeal stridor) plus either</p><p class="depth0">cataract or evidence of increased intracranial pressure (such</p><p class="depth0">as papilledema)..............................................</p><p class="depth0">Marked neuromuscular excitability, or; paresthesias (of arms,       60</p><p class="depth0">legs, or circumoral area) plus either cataract or evidence of</p><p class="depth0">increased intracranial pressure..............................</p><p class="depth0">Continuous medication required for control....................      107907 Cushing's syndrome</p><p class="depth0">As active, progressive disease including loss of muscle            100</p><p class="depth0">strength, areas of osteoporosis, hypertension, weakness, and</p><p class="depth0">enlargement of pituitary or adrenal gland....................</p><p class="depth0">Loss of muscle strength and enlargement of pituitary or             60</p><p class="depth0">adrenal gland................................................</p><p class="depth0">With striae, obesity, moon face, glucose intolerance, and           30</p><p class="depth0">vascular fragility...........................................</p><p class="depth0">Note: With recovery or control, evaluate as residuals of</p><p class="depth0">adrenal insufficiency or cardiovascular, psychiatric, skin,</p><p class="depth0">or skeletal complications under appropriate diagnostic code.7908 Acromegaly</p><p class="depth0">Evidence of increased intracranial pressure (such as visual        100</p><p class="depth0">field defect), arthropathy, glucose intolerance, and either</p><p class="depth0">hypertension or cardiomegaly.................................</p><p class="depth0">Arthropathy, glucose intolerance, and hypertension............      60</p><p class="depth0">Enlargement of acral parts or overgrowth of long bones, and         30</p><p class="depth0">enlarged sella turcica.......................................7909 Diabetes insipidus</p><p class="depth0">Polyuria with near-continuous thirst, and more than two            100</p><p class="depth0">documented episodes of dehydration requiring parenteral</p><p class="depth0">hydration in the past year...................................</p><p class="depth0">Polyuria with near-continuous thirst, and one or two                60</p><p class="depth0">documented episodes of dehydration requiring parenteral</p><p class="depth0">hydration in the past year...................................</p><p class="depth0">Polyuria with near-continuous thirst, and one or more episodes      40</p><p class="depth0">of dehydration in the past year not requiring parenteral</p><p class="depth0">hydration....................................................</p><p class="depth0">Polyuria with near-continuous thirst..........................      207911 Addison's disease (Adrenal Cortical Hypofunction)</p><p class="depth0">Four or more crises during the past year......................      60</p><p class="depth0">Three crises during the past year, or; five or more episodes        40</p><p class="depth0">during the past year.........................................</p><p class="depth0">One or two crises during the past year, or; two to four             20</p><p class="depth0">episodes during the past year, or; weakness and fatigability,</p><p class="depth0">or; corticosteroid therapy required for control..............</p><p class="depth0">Note (1): An Addisonian ``crisis'' consists of the rapid onset</p><p class="depth0">of peripheral vascular collapse (with acute hypotension and</p><p class="depth0">shock), with findings that may include: anorexia; nausea;</p><p class="depth0">vomiting; dehydration; profound weakness; pain in abdomen,</p><p class="depth0">legs, and back; fever; apathy, and depressed mentation with</p><p class="depth0">possible progression to coma, renal shutdown, and death.</p><p class="depth0">Note (2): An Addisonian ``episode,'' for VA purposes, is a</p><p class="depth0">less acute and less severe event than an Addisonian crisis</p><p class="depth0">and may consist of anorexia, nausea, vomiting, diarrhea,</p><p class="depth0">dehydration, weakness, malaise, orthostatic hypotension, or</p><p class="depth0">hypoglycemia, but no peripheral vascular collapse.</p><p class="depth0">Note (3): Tuberculous Addison's disease will be evaluated as</p><p class="depth0">active or inactive tuberculosis. If inactive, these</p><p class="depth0">evaluations are not to be combined with the graduated ratings</p><p class="depth0">of 50 percent or 30 percent for non-pulmonary tuberculosis</p><p class="depth0">specified under Sec.   4.88b. Assign the higher rating.7912 Pluriglandular syndrome</p><p class="depth0">Evaluate according to major manifestations.7913 Diabetes mellitus</p><p class="depth0">Requiring more than one daily injection of insulin, restricted     100</p><p class="depth0">diet, and regulation of activities (avoidance of strenuous</p><p class="depth0">occupational and recreational activities) with episodes of</p><p class="depth0">ketoacidosis or hypoglycemic reactions requiring at least</p><p class="depth0">three hospitalizations per year or weekly visits to a</p><p class="depth0">diabetic care provider, plus either progressive loss of</p><p class="depth0">weight and strength or complications that would be</p><p class="depth0">compensable if separately evaluated..........................</p><p class="depth0">Requiring insulin, restricted diet, and regulation of               60</p><p class="depth0">activities with episodes of ketoacidosis or hypoglycemic</p><p class="depth0">reactions requiring one or two hospitalizations per year or</p><p class="depth0">twice a month visits to a diabetic care provider, plus</p><p class="depth0">complications that would not be compensable if separately</p><p class="depth0">evaluated....................................................</p><p class="depth0">Requiring insulin, restricted diet, and regulation of               40</p><p class="depth0">activities...................................................</p><p class="depth0">Requiring insulin and restricted diet, or; oral hypoglycemic        20</p><p class="depth0">agent and restricted diet....................................</p><p class="depth0">Manageable by restricted diet only............................      10</p><p class="depth0">Note (1): Evaluate compensable complications of diabetes</p><p class="depth0">separately unless they are part of the criteria used to</p><p class="depth0">support a 100 percent evaluation. Noncompensable</p><p class="depth0">complications are considered part of the diabetic process</p><p class="depth0">under diagnostic code 7913.</p><p class="depth0">Note (2): When diabetes mellitus has been conclusively</p><p class="depth0">diagnosed, do not request a glucose tolerance test solely for</p><p class="depth0">rating purposes.7914 Neoplasm, malignant, any specified part of the endocrine        100</p><p class="depth0">system.........................................................</p><p class="depth0">Note: A rating of 100 percent shall continue beyond the</p><p class="depth0">cessation of any surgical, X-ray, antineoplastic chemotherapy</p><p class="depth0">or other therapeutic procedure. Six months after</p><p class="depth0">discontinuance of such treatment, the appropriate disability</p><p class="depth0">rating shall be determined by mandatory VA examination. Any</p><p class="depth0">change in evaluation based upon that or any subsequent</p><p class="depth0">examination shall be subject to the provisions of Sec.</p><p class="depth0">3.105(e) of this chapter. If there has been no local</p><p class="depth0">recurrence or metastasis, rate on residuals.7915 Neoplasm, benign, any specified part of the endocrine</p><p class="depth0">system rate as residuals of endocrine dysfunction.</p><p class="depth0">7916 Hyperpituitarism (prolactin secreting pituitary</p><p class="depth0">dysfunction)7917 Hyperaldosteronism (benign or malignant)7918 Pheochromocytoma (benign or malignant)</p><p class="depth0">Note: Evaluate diagnostic codes 7916, 7917, and 7918 as</p><p class="depth0">malignant or benign neoplasm as appropriate.7919 C-cell hyperplasia of the thyroid..........................     100</p><p class="depth0">Note: A rating of 100 percent shall continue beyond the</p><p class="depth0">cessation of any surgical, X-ray, antineoplastic chemotherapy</p><p class="depth0">or other therapeutic procedure. Six months after</p><p class="depth0">discontinuance of such treatment, the appropriate disability</p><p class="depth0">rating shall be determined by mandatory VA examination. Any</p><p class="depth0">change in evaluation based upon that or any subsequent</p><p class="depth0">examination shall be subject to the provisions of Sec.</p><p class="depth0">3.105(e) of this chapter. If there has been no local</p><p class="depth0">recurrence or metastasis, rate on residuals.------------------------------------------------------------------------

[61 FR 20446, May 7, 1996]</p><p class="depth0">Neurological Conditions and Convulsive Disorders</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§.
          Code available <a href="https://github.com/anthonygarvan/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5
      </div>
    </div>
  </footer>
  </body>
</html>
